Joana Fernandes, PhD,  —

Joana brings more than 8 years of academic research and experience as well as Scientific writing and editing to her role as a Science and Research writer. She also served as a Postdoctoral Researcher at the Center for Neuroscience and Cell Biology in Coimbra, Portugal, where she also received her PhD in Health Science and Technologies, with a specialty in Molecular and Cellular Biology.

Articles by Joana Fernandes

Samumed’s Candidate PF Therapy, SM04646, Found to Be Well-tolerated and Safe in Phase 1 Trial

Samumed’s nebulized inhalation solution SM04646, a candidate therapy to treat idiopathic pulmonary fibrosis (IPF), was found to be well-tolerated and to cause no serious adverse effects in a Phase 1 trial of healthy individuals in Australia. These results support the launch of future clinical trials to test the drug’s efficacy in IPF patients. According to…

Only Half of IPF Patients Talk to Doctors About Treatments

Patients with idiopathic pulmonary fibrosis (IPF) want more information from their doctors at diagnosis, according to the results of a new survey. Researchers said that only half of patients surveyed report discussing antifibrotic treatment decisions with their doctors when they’re diagnosed. Results of the survey study, titled “Differences in…

Bellerophon’s INOpulse Inhaled Nitrous Oxide Device Improves Symptoms of PH-IPF Patients, Study Finds

INOpulse has shown promise in treating patients with pulmonary hypertension associated with idiopathic pulmonary fibrosis (PH-IPF), concludes a study by Bellerophon Therapeutics, developer of the inhaled nitrous oxide device. The study, “Unraveling the Mode of Action of Pulsed Inhaled NO in Severe IPF Using Functional Respiratory Imaging.” showed that PH-IPF…

IPF Patients on Esbriet Live Approximately 2.5 Years Longer Than Untreated Patients, Study Finds

Esbriet (pirfenidone) improved life expectancy in patients with idiopathic pulmonary fibrosis (IPF) by approximately 2.5 years compared to best supportive care, according to recent research. The study, “Predicting Life Expectancy For Pirfenidone In Idiopathic Pulmonary Fibrosis,” was published in the Journal of Managed Care Pharmacy. Esbriet has been…

Your PF Community

Woman laying down reading

Visit the Pulmonary Fibrosis News forums to connect with others in the PF community.

View Forums